You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Novel Small Molecule Macrophage Inhibitors for the Treatment of Retinal Diseases

    SBC: Eyedesis Biosciences, LLC            Topic: N

    PROJECT SUMMARY ABSTRACT Persistent disease activity PDA in spite of anti vascular endothelial growth factor VEGF therapy remains a significant clinical unmet need for patients with neovascular age related macular degeneration NVAMD The purpose of this STTR Phase I grant application is to develop novel therapies that will be effective for the treatment of PDA associated with NVAMD The cu ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Personalized Neural Stem Cell Therapy for Cancer

    SBC: Falcon Therapeutics, Inc.            Topic: NCATS

    Project Summary Abstract Glioblastoma GBM is the most common primary brain tumor and one of the deadliest forms of cancer Standard surgery chemotherapy and radiation fail to eliminate the infiltrative invasive cancer cells Median survival remains only months Drugs that seek out the disseminated GBM cells behind the blood brain barrier will prevent the inevitable recurrence in patients ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Development Characterization and Commercialization of a Viably Frozen Patient Inclusive Hepatocellular Carcinoma Tumor Bank

    SBC: Woodland Pharmaceuticals LLC            Topic: 103

    Abstract Hepatocellular carcinoma HCC is a disease of growing incidence globally including in the US by per year With the recent success of anti viral therapies the etiology of HCC in the American population is projected to shift from viral HBV HCV hepatitis to primarily fatty liver disease in the near future Currently only one effective systemic therapy has been developed for HCC ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Development of PAR Pepducins as a Novel Antithrombotic Treatment

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Coronary artery disease remains the leading cause of death in the United States Platelets play an important role in the pathogenesis of acute coronary syndrome ACS as platelet activation aggregation and secretion are key components of arterial thrombus formation Despite dual anti platelet therapy for ACS and percutaneous coronary interventions PCI many patients sustain a high incidence u ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. UV emitting nanoparticles as novel radiation sensitizers targeting hypoxic cells

    SBC: Radiation Monitoring Devices, Inc.            Topic: 102

    Project Summary Abstract Radiation therapy is one of the primary therapeutic techniques for treating cancer Nearly two thirds of all cancer patients will receive radiation therapy during their illness with an average of radiation treatment episodes Although largely effective radiation therapy like other forms of cancer treatment has difficulty killing hypoxic regions within solid tumors ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. High throughput CRISPR Cas cell line generation using the CellRaft Array platform

    SBC: Cell Microsystems, Inc.            Topic: NHGRI

    Project Summary Genome editing technologies such CRISPR Cas provide a rapid and targeted means of both knocking out gene expression and knocking in gene modifications However the current workflow required for CRISPR cell line generation relies on several technologies which reduce throughput efficiency and the overall viability of genome edited cells Cell Microsystems has developed a single ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Artificial neural networks for high performance fully automated particle tracking analysis even at low signal to noise regimes

    SBC: AI Tracking Solutions LLC            Topic: 400

    Abstract Particle tracking PT is a powerful biophysical tool for elucidating molecular interactions transport phenomena and rheological properties in complex biological environments Unfortunately PT remains a niche tool in life and physical sciences with a limited user base in large part due to significant time and technical constraints in extracting accurate time variant positional data fr ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a new therapeutic agent for retinal ciliopathies

    SBC: Rescindo Therapeutics Inc            Topic: N

    The ciliopathies are a group of andgt overlapping clinical disorders caused by defects in the primary cilium and its anchoring structure the basal body Although individually rare this group contributes significantly to the population genetic disease burden with some estimates placing their combined incidence to as much as Importantly although some ciliopathies are lethal most pat ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Ultrasound Based Device to Guide Treatment of Graft Versus Host Disease Using Skin Elasticity as a Biomarker

    SBC: Microelastic Ultrasound Systems, Inc.            Topic: 102

    Ultrasound Based Device to Guide Treatment of Graft Versus Host Disease using Skin Elasticity as a Biomarker ABSTRACT Sclerotic chronic graft versus host disease cGVHD develops in of allogenic Human Stem Cell Transplant HCT recipients and is associated with significant morbidity and mortality GVHD is treated with immunosuppression which puts patients at severe risk of infection ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. AML MutationCounter a tool to detect residual and recurrent leukemia

    SBC: Asystbio Laboratories, LLC            Topic: 102

    Abstract AsystBio LLC proposes to market a molecular tool kit called AML MutationCounter to count somatic mutations in genes that contribute to the development of acute myeloid leukemia AML We have developed a set of reagents and computer programs for application of next generation sequencing to count AML gene mutations The tool kit is versatile and can be used with either of the two major DNA ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government